Comparison

ALNYLAM PHARMACEUTICALS, INC. (ALNY) vs Jazz Pharmaceuticals plc (JAZZ)

The same filed metrics for both companies, side by side.

What each names as a risk in its own annual report, how each is priced against its own history, and the tracked managers whose latest 13F reports a position in both.

Financials

ALNY

ALNYLAM PHARMACEUTICALS, INC.

Biotechnology

Revenue, FY25: $3.71B
Net income: $314M
Operating cash flow: $524M
Free cash flow: $465M
Net margin: 8.45%
Operating margin: 13.51%
Gross margin: 81.77%

JAZZ

Jazz Pharmaceuticals plc

Biotechnology

Revenue, FY25: $4.27B
Net income: −$356M
Operating cash flow: $1.36B
Free cash flow: -
Net margin: −8.35%
Operating margin: −10.08%
Gross margin: -

Head-to-head

Filed growth, quality and valuation, read against each company’s own history rather than against the other side.

Metric	ALNY	JAZZ
Revenue growth, latest filed year	+65.19%	+4.88%
Piotroski F-score	5 of 8	5 of 8
P/E against its own history	-	10.88% below

What each says it is exposed to

From Item 1A of each company’s most recent 10-K.

ALNY

FDA approval
Reimbursement
Data privacy
Litigation
Tax
Product recalls

And 15 more.

JAZZ

FDA approval
Reimbursement
Litigation
Debt covenants
Tariffs
Cybersecurity

And 15 more.

Tracked managers holding both

Joel Greenblatt Gotham Asset Management 0.03% · 0.06%

Updated Aug 31, 2026 · the newer of the two companies' filings